Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,304 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,827 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02920008 | Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia | completed | Phase 3 | 302 | Astex Pharmaceuticals, Inc.INDUSTRY | 15 | Aug 28, 2024 | clinicaltrials |
| NCT02348489 | SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction | completed | Phase 3 | 815 | Astex Pharmaceuticals, Inc.INDUSTRY | 24 | Aug 27, 2024 |
| NCT02907359 | Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs | completed | Phase 3 | 417 | Astex Pharmaceuticals, Inc.INDUSTRY | 14 | Aug 27, 2024 | clinicaltrials |
| NCT03306264 | Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML | completed | Phase 3 | 227 | Astex Pharmaceuticals, Inc.INDUSTRY | 10 | Aug 27, 2024 | clinicaltrials |
| NCT06573645 | A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL | not yet recruiting | Phase 3 | 428 | Xia YiOTHER | 0 | Aug 27, 2024 | clinicaltrials |
| NCT06475820 | Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis | active not recruiting | Phase 2 / Phase 3 | 150 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Aug 23, 2024 | clinicaltrials |
| NCT00877214 | Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas(MAINTAIN) | unknown | Phase 3 | 1,272 | Jurgen BarthOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT00991211 | Bendamustine Plus Rituximab Versus CHOP Plus Rituximab | completed | Phase 3 | 549 | University of GiessenOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT01456351 | Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab | completed | Phase 3 | 230 | University of GiessenOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT02131753 | Therapy Optimisation for the Treatment of Hairy Cell Leukemia | recruiting | Phase 2 / Phase 3 | 210 | University of GiessenOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT03110562 | Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma(BOSTON) | completed | Phase 3 | 402 | Karyopharm Therapeutics IncINDUSTRY | 21 | Aug 21, 2024 | clinicaltrials |
| NCT06187441 | FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)(HOVON174MM) | recruiting | Phase 3 | 599 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 1 | Aug 19, 2024 | clinicaltrials |
| NCT02326311 | Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response | completed | Phase 3 | 229 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT05290545 | Haplo-PBSC+Cord vs Haplo-PBSC+BM for Hematological Malignancies Undergoing Allo-HSCT | completed | Phase 3 | 314 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06548347 | A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma | not yet recruiting | Phase 2 / Phase 3 | 606 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 0 | Aug 12, 2024 | clinicaltrials |
| NCT06544109 | Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients(Ven APL) | enrolling by invitation | Phase 2 / Phase 3 | 98 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT03275636 | Haploidentical Donor vs mMUD in Hematological Malignancies(HAMLET) | completed | Phase 2 / Phase 3 | 98 | DKMS gemeinnützige GmbHOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT02668653 | Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)(QuANTUM-First) | completed | Phase 3 | 539 | Daiichi SankyoINDUSTRY | 28 | Aug 6, 2024 | clinicaltrials |
| NCT06522555 | The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma | recruiting | Phase 3 | 100 | Ruijin HospitalOTHER | 1 | Aug 5, 2024 | clinicaltrials |
| NCT00043381 | Decitabine Versus Supportive Care in Adults With Advanced-stage MDS | completed | Phase 3 | 160 | Astex Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT02323022 | Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML) | completed | Phase 3 | 618 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT03616470 | Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia | terminated | Phase 3 | 388 | GlycoMimetics IncorporatedINDUSTRY | 9 | Jul 29, 2024 | clinicaltrials |
| NCT06520176 | Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients | recruiting | Phase 3 | 99 | The Affiliated People's Hospital of Ningbo UniversityOTHER_GOV | 1 | Jul 25, 2024 | clinicaltrials |
| NCT06521255 | Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | recruiting | Phase 3 | 244 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Jul 25, 2024 | clinicaltrials |
| NCT00551928 | Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma Patients(MPRvsMEL200) | completed | Phase 3 | 402 | Fondazione EMN Italy OnlusOTHER | 1 | Jul 22, 2024 | clinicaltrials |
| NCT02215980 | STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS | completed | Phase 3 | 210 | Fondazione EMN Italy OnlusOTHER | 1 | Jul 22, 2024 | clinicaltrials |
| NCT00557193 | Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | completed | Phase 3 | 218 | Children's Oncology GroupNETWORK | 4 | Jul 15, 2024 | clinicaltrials |
| NCT06496308 | Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment | recruiting | Phase 3 | 78 | Ruijin HospitalOTHER | 1 | Jul 11, 2024 | clinicaltrials |
| NCT03952091 | TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma | completed | Phase 3 | 289 | TJ Biopharma Co., Ltd.INDUSTRY | 2 | Jul 3, 2024 | clinicaltrials |
| NCT05029531 | Combined Immuno-chemotherapy for Patients With B-linear Acute Lymphoblastic Leukemia Diagnosed From 0 to 365 Days of Life (ALL-Baby-2021) | recruiting | Phase 3 | 80 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT06465446 | A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma | not yet recruiting | Phase 3 | 202 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 0 | Jun 24, 2024 | clinicaltrials |
| NCT06297772 | Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR | not yet recruiting | Phase 3 | 220 | Ruijin HospitalOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT06232707 | A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)(ALUMMINATE) | withdrawn | Phase 3 | 0 | CelgeneINDUSTRY | 27 | May 31, 2024 | clinicaltrials |
| NCT06434467 | The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma | unknown | Phase 3 | 83 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 30, 2024 | clinicaltrials |
| NCT03234972 | A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 3 | 213 | Janssen Research & Development, LLCINDUSTRY | 2 | May 29, 2024 | clinicaltrials |
| NCT06418776 | IMPACT-AML: Randomized Pragmatic Clinical Trial for Relapsed or Refractory AML | recruiting | Phase 3 | 198 | National Research Center for Hematology, RussiaNETWORK | 1 | May 17, 2024 | clinicaltrials |
| NCT01788020 | Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia | completed | Phase 3 | 202 | University of UlmOTHER | 1 | May 13, 2024 | clinicaltrials |
| NCT02661503 | HD21 for Advanced Stages | unknown | Phase 3 | 1,500 | University of CologneOTHER | 1 | May 13, 2024 | clinicaltrials |
| NCT04061512 | Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia(RAINBOW) | recruiting | Phase 2 / Phase 3 | 148 | University College, LondonOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT00112931 | Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma | completed | Phase 3 | 462 | University College, LondonOTHER | 3 | May 9, 2024 | clinicaltrials |
| NCT00678327 | Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma | completed | Phase 3 | 1,202 | University College, LondonOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT05403580 | Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer | withdrawn | Phase 3 | 0 | Mayo ClinicOTHER | 0 | May 6, 2024 | clinicaltrials |
| NCT06381817 | Haplo-cord HCT vs. Haplo-HCT for T-ALL Patients | recruiting | Phase 3 | 146 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 26, 2024 | clinicaltrials |
| NCT01728805 | Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL | completed | Phase 3 | 372 | Kyowa Kirin, Inc.INDUSTRY | 11 | Apr 25, 2024 | clinicaltrials |
| NCT03217812 | A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region) | completed | Phase 3 | 220 | Janssen Research & Development, LLCINDUSTRY | 5 | Apr 25, 2024 | clinicaltrials |
| NCT06179732 | Field Evaluations of Innovative Tools for Vector-borne Disease Control in Conflict-affected Communities | completed | Phase 3 | 2,400 | The Mentor InitiativeOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT01751997 | Family-mismatched/Haploidentical Donors Versus Matched Unrelated Donors | completed | Phase 2 / Phase 3 | 116 | Byung-Sik ChoOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT03801525 | Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)(ULTRA-V) | terminated | Phase 2 / Phase 3 | 277 | TG Therapeutics, Inc.INDUSTRY | 1 | Apr 19, 2024 | clinicaltrials |
| NCT04571645 | Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia(AML) | terminated | Phase 3 | 9 | Jazz PharmaceuticalsINDUSTRY | 1 | Apr 15, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Aug 28, 2024source: clinicaltrials